Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells
Christoph Becker, … , Ingo Autenrieth, Markus F. Neurath
Christoph Becker, … , Ingo Autenrieth, Markus F. Neurath
Published September 1, 2003
Citation Information: J Clin Invest. 2003;112(5):693-706. https://doi.org/10.1172/JCI17464.
View: Text | PDF
Article Immunology

Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells

  • Text
  • PDF
Abstract

IL-12 p40–related cytokines such as IL-12 p35/p40 heterodimer and IL-23 (p19/p40) are potent regulators of adaptive immune responses. Little is known, however, about the transcriptional regulation of the p40 gene in vivo. In an attempt toward this goal, we have generated transgenic mice expressing firefly luciferase under the control of the IL-12 p40 promoter. High constitutive transgene expression was found in the small intestine only, whereas little reporter gene activity was observed in other tissues. Within the small bowel, constitutive promoter activity was restricted to the terminal ileum and associated with high expression of p40 mRNA as well as p40 and IL-23 p19/p40 proteins. The cells constitutively producing IL-12 p40 were identified as CD8α and CD11b double-negative CD11c+ lamina propria dendritic cells (LPDCs) that represent a major cell population in the lamina propria of the small intestine, but not in the colon. FISH directly demonstrated the uptake of bacteria by a subset of LPDCs in the terminal ileum that was associated with p40 expression. Furthermore, little or no p40 protein expression in LPDCs was found in the terminal ileum of germfree mice, indicating a key role of the intestinal flora for constitutive p40 expression. In addition, analysis of transgenic mice with a mutated NF-κB target site in the p40 promoter showed a critical role of NF-κB for constitutive transgene expression. Our data reveal important functional differences between the mucosal immune systems of the small and large bowel in healthy mice and suggest that the high bacterial load in the terminal ileum activates p40 gene transcription in LPDCs through NF-κB. These data suggest a predisposition of the terminal ileum to develop chronic inflammatory responses through IL-23 and thus may provide a molecular explanation for the preferential clinical manifestation of Crohn disease in this part of the gut.

Authors

Christoph Becker, Stefan Wirtz, Manfred Blessing, Jaana Pirhonen, Dennis Strand, Oliver Bechthold, Julia Frick, Peter R. Galle, Ingo Autenrieth, Markus F. Neurath

×

Figure 8

Options: View larger image (or click on image) Download as PowerPoint
Bacteria in the distal small intestine drive constitutive intestinal IL-...
Bacteria in the distal small intestine drive constitutive intestinal IL-12 p40 expression. (a) Western blot for IL-12 p40 of gut samples (D1 plus D2: p; D3 to D4: d) derived from three mice (M1, M2, M3) bred under germfree conditions (control), no constitutive p40 protein expression was seen under germfree conditions. The number of CD11c+ LPDCs in the terminal ileum of germfree mice was comparable to that in the ileum of mice bred under specific pathogen-free conditions, as demonstrated by immunofluorescence analysis (right panel) and quantification of fluorescence-positive cells (not shown). (b) FISH analysis on CD11c-enriched lamina propria cells from the distal small intestine of healthy FVB mice using a universal, FITC-labeled eubacterial oligonucleotide probe (EUB-338) and simultaneous immunocytochemical analysis of IL-12 p40 expression. Three representative high-power fields are shown. Image arithmetic (overlay) demonstrated colocalization of bacteria and p40 protein expression in CD11c-enriched lamina propria cells. The CD11c-enriched lamina propria cells did not express CD8α or CD11b, as shown by double-staining analysis (not shown). (c) FISH analysis of CD11c enriched lamina propria cells of the distal small intestine of healthy p40 promoter transgenic FVB mice using a universal, FITC-labeled eubacterial oligonucleotide probe (EUB-338) and simultaneous immunohistochemical analysis of luciferase expression. Colocalization of bacteria and luciferase protein expression was noted in lamina propria cells. No staining was observed using a control probe (NONEUB-338) complementary to EUB-338 to exclude nonspecific binding (not shown).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts